These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 2287060)

  • 21. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Nov; 48(11):1627-57. PubMed ID: 8558754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Sep; 48(9):1131-60. PubMed ID: 7474333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antimicrobial activities of ceftazidime on fresh clinical isolates].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Suzuki K; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1992 Nov; 45(11):1421-50. PubMed ID: 1494227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Nationwide survey of susceptibilities of clinical isolates to antibacterial agents in 1992].
    Tabe Y; Igari J
    Jpn J Antibiot; 1997 Feb; 50(2):178-86. PubMed ID: 9100077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
    Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antimicrobial susceptibility and prevalence of beta-lactamase producing clinical isolates in southern Kyushu. The results of collaborative study from 1999 to 2000].
    Nakasone I; Onaga S; Fukunaga H; Saitoh H; Yamane N; Sato Y
    Jpn J Antibiot; 2002 Sep; 55 Suppl A():95-110. PubMed ID: 12599533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
    Ikemoto H; Ito C; Yoshida T; Watanabe K; Mori T; Ohno I; Okada S; Igari J; Arakawa M; Igarashi K; Oguri T; Okada M; Ozaki K; Terai T; Aoki N; Inoue H; Nakadate T; Kitamura N; Sekine O; Suzuki Y; Ando M; Suga M; Sato K; Nakata K; Kusano N
    Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
    Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of minocycline and cefuzonam for antimicrobial activity against clinical isolates.
    Igari J; Oguri T; Higuchi T
    Jpn J Antibiot; 1994 Aug; 47(8):1013-29. PubMed ID: 7933531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical laboratory approach to estimating the effective administration dose of imipenem/cilastatin. Evaluation of the disk susceptibility test and its interpretation system].
    Matsuo K; Uete T
    Jpn J Antibiot; 1989 Nov; 42(11):2377-92. PubMed ID: 2621780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antimicrobial activity of cefodizime against fresh clinical isolates].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Nakane Y; Suzuki K
    Jpn J Antibiot; 1993 Oct; 46(10):860-76. PubMed ID: 8254888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antibacterial activities of sisomicin against fresh clinical isolates].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Suzuki K; Fukayama S; Ishihara R; Oda S; Tanaka S; Nakane Y
    Jpn J Antibiot; 1992 Aug; 45(8):990-1002. PubMed ID: 1433905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Takanashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Kosakai N; Yamaguchi K; Matsumoto T; Kashitani F; Tanaka M
    Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antibacterial activities of ofloxacin against recent isolates from patients with community-acquired infections].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1991 Sep; 44(9):941-57. PubMed ID: 1960856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of aztreonam against gram negative bacteria from clinical specimens and its comparison with other commonly used antibiotics.
    Qadri SM; Belobraydic KA
    Methods Find Exp Clin Pharmacol; 1986 Apr; 8(4):223-6. PubMed ID: 3088346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity and beta-lactamase stability of LJC 10,627.
    Neu HC; Gu JW; Fang W; Chin NX
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1418-23. PubMed ID: 1510436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
    Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
    Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative in vitro activity of biapenem, a new carbapenem antibiotic.
    Clarke AM; Zemcov SJ
    Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):377-84. PubMed ID: 8354306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
    McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1992)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Tanimoto H; Nakata K; Nakamori Y; Nakatani T; Kusano N
    Jpn J Antibiot; 1996 Jan; 49(1):34-70. PubMed ID: 8851305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.